PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Vistagen to continue social anxiety nasal spray trials

Vistagen Therapeutics announced this week that it will proceed with its Phase 3 clinical trial assessing drug candidate PH94B for adults with Social Anxiety Disorder (SAD), after an independent team of biostatisticians evaluated trial results and recommended that the study should continue as planned.

Following disappointing results from a previous trial, PALISADE-1, the company recruited independent scientists to conduct an interim analysis and map out the best course of action for PALISADE-2. Notably, PH94B demonstrated tolerability in the PALISADE-1 trial, and no severe or serious adverse events were reported. 

The company is focused on developing central nervous system therapeutics to ‘transform the landscape for individuals living with anxiety, depression, and other central nervous systems (CNS) disorders.” Vistagen says it’s specifically focused on producing drugs that are faster-acting than those that are currently available.

Currently, Vistagen is betting on PH04B and PH10, which both belong to a new class of drugs known as pherines, an odourless and tasteless investigational neuroactive steroid nasal spray that activates chemosensory neurons in the nasal passages and can affect the olfactory-amygdala neural circuits without affecting the rest of the body, or direct activity on CNS neurons.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026